Literature DB >> 12140559

Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy.

Steven A Moore1, Fumiaki Saito, Jianguo Chen, Daniel E Michele, Michael D Henry, Albee Messing, Ronald D Cohn, Susan E Ross-Barta, Steve Westra, Roger A Williamson, Toshinori Hoshi, Kevin P Campbell.   

Abstract

Fukuyama congenital muscular dystrophy (FCMD), muscle-eye-brain disease (MEB), and Walker-Warburg syndrome are congenital muscular dystrophies (CMDs) with associated developmental brain defects. Mutations reported in genes of FCMD and MEB patients suggest that the genes may be involved in protein glycosylation. Dystroglycan is a highly glycosylated component of the muscle dystrophin-glycoprotein complex that is also expressed in brain, where its function is unknown. Here we show that brain-selective deletion of dystroglycan in mice is sufficient to cause CMD-like brain malformations, including disarray of cerebral cortical layering, fusion of cerebral hemispheres and cerebellar folia, and aberrant migration of granule cells. Dystroglycan-null brain loses its high-affinity binding to the extracellular matrix protein laminin, and shows discontinuities in the pial surface basal lamina (glia limitans) that probably underlie the neuronal migration errors. Furthermore, mutant mice have severely blunted hippocampal long-term potentiation with electrophysiologic characterization indicating that dystroglycan might have a postsynaptic role in learning and memory. Our data strongly support the hypothesis that defects in dystroglycan are central to the pathogenesis of structural and functional brain abnormalities seen in CMD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12140559     DOI: 10.1038/nature00838

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  196 in total

Review 1.  The Finnish Disease Heritage III: the individual diseases.

Authors:  Reijo Norio
Journal:  Hum Genet       Date:  2003-03-08       Impact factor: 4.132

2.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

Review 3.  Congenital muscular dystrophies: toward molecular therapeutic interventions.

Authors:  James Collins; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

Review 4.  Extracellular matrix: functions in the nervous system.

Authors:  Claudia S Barros; Santos J Franco; Ulrich Müller
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 5.  The impact of the extracellular matrix on inflammation.

Authors:  Lydia Sorokin
Journal:  Nat Rev Immunol       Date:  2010-10       Impact factor: 53.106

6.  RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.

Authors:  C A Dwyer; E Baker; H Hu; R T Matthews
Journal:  Neuroscience       Date:  2012-06-19       Impact factor: 3.590

7.  GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

Authors:  Braden S Jensen; Tobias Willer; Dimah N Saade; Mary O Cox; Tahseen Mozaffar; Mena Scavina; Vikki A Stefans; Thomas L Winder; Kevin P Campbell; Steven A Moore; Katherine D Mathews
Journal:  Hum Mutat       Date:  2015-09-23       Impact factor: 4.878

Review 8.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

9.  Cloning and expression patterns of dystroglycan during the early development of Xenopus laevis.

Authors:  Nicole Moreau; Dominique Alfandari; Alban Gaultier; Hélène Cousin; Thierry Darribère
Journal:  Dev Genes Evol       Date:  2003-05-09       Impact factor: 0.900

10.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality.

Authors:  Tobias Willer; Belén Prados; Juan Manuel Falcón-Pérez; Ingrid Renner-Müller; Gerhard K H Przemeck; Mark Lommel; Antonio Coloma; M Carmen Valero; Martin Hrabé de Angelis; Widmar Tanner; Eckhard Wolf; Sabine Strahl; Jesús Cruces
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.